Profile data is unavailable for this security.
About the company
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
- Revenue in USD (TTM)5.00m
- Net income in USD-104.87m
- Incorporated2018
- Employees127.00
- LocationAdlai Nortye Ltdc/o Ugland HousePO Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
- Phone+1 8 482307430
- Websitehttp://www.adlainortye.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 250.66m | 133.00 | -- | 1.36 | -- | 235.58 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Sanara Medtech Inc | 68.00m | -4.89m | 256.17m | 107.00 | -- | 5.92 | -- | 3.77 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
MacroGenics Inc | 43.36m | -23.24m | 256.17m | 339.00 | -- | 2.41 | -- | 5.91 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 260.12m | 158.00 | -- | 0.7577 | -- | 7.79 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Aquestive Therapeutics Inc | 51.50m | -28.77m | 262.19m | 135.00 | -- | -- | -- | 5.09 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 262.48m | 122.00 | -- | 2.51 | -- | 366.04 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 264.11m | 145.00 | -- | 1.59 | -- | 3.62 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
ASP Isotopes Inc | 1.27m | -19.62m | 264.51m | 76.00 | -- | 23.61 | -- | 207.72 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -37.37m | 264.73m | 42.00 | -- | 43.68 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 267.90m | 127.00 | -- | 3.37 | -- | 53.58 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Black Diamond Therapeutics Inc | 0.00 | -79.79m | 268.89m | 54.00 | -- | 2.41 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 277.31m | 140.00 | -- | 35.86 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
Medifast Inc | 897.81m | 67.76m | 281.52m | 634.00 | 4.15 | 1.33 | 3.47 | 0.3136 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Mersana Therapeutics Inc | 38.30m | -134.81m | 285.10m | 123.00 | -- | 10.19 | -- | 7.44 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Holder | Shares | % Held |
---|---|---|
Cantor Fitzgerald & Co.as of 31 Mar 2024 | 40.31k | 0.13% |
Millennium Management LLCas of 31 Mar 2024 | 20.03k | 0.06% |
Qube Research & Technologies Ltd.as of 31 Mar 2024 | 84.00 | 0.00% |